Thanks for sharing your experience with us.
From my point of view, this news is at least the first good news indicating the company is on the right track of transformation into producing generic products, which is better than some companies keep consuming shareholders’ money and do nothing.
And from the presentation, they also have another two products this year to apply for approval. Small steps may gradually form a big progress.
Hope they still have a lot of cash for product development, wait for the annual report.
And always be cautious with trading.
Add to My Watchlist
What is My Watchlist?
